Other languages Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
22 ^USD	+4.61%		+20.48%	+6.37%

23/04	Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target	MT
14/03	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	14/03
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee	05/03
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	05/03
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	08/01
Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of the Board, Compensation and Nominating and Corporate Governance Committees	28/11
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Sector Update: Health Care Stocks Gain in Late Afternoon Trading	14/11
Selecta Biosciences Merges With Cartesian Therapeutics	14/11
Cartesian Therapeutics, Inc. acquired Selecta Biosciences, Inc. for approximately $380 million, in a reverse merger transaction.	13/11
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	01/23/01
Peter Traber, Selecta Biosciences, Inc.?s Chief Medical Officer, Moves to Part-Time Status as Chief Medical Officer, Effective as of November 6, 2023	01/23/01
Selecta Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17
Selecta Biosciences Says Phase 3 Studies of Investigational Gout Medicine Met Primary Efficacy Endpoints	31/23/31
Selecta Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04
Sector Update: Health Care Stocks Mixed Premarket Tuesday	21/23/21
Fed Meeting in Focus as US Equity Futures Extend Gains on Easing Bank Fears	21/23/21
Sector Update: Healthcare	21/23/21
Top Premarket Gainers	21/23/21
Selecta Biosciences, Swedish Orphan Biovitrum Say Phase 3 Trials of Gout Drug Candidate Meet Primary Endpoints	21/23/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Other languages

Filters